<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05039580</url>
  </required_header>
  <id_info>
    <org_study_id>EBV and CAEBV 001</org_study_id>
    <nct_id>NCT05039580</nct_id>
  </id_info>
  <brief_title>Programmed Cell Death Protein-1 (PD-1) Monoclonal Antibody for EBV-HLH and CAEBV as First-line Therapy</brief_title>
  <acronym>SEHC</acronym>
  <official_title>A Clinical Trial of PD-1 Monoclonal Antibody as First-line Induction Therapy for EBV-associated Hemophagocytic Syndrome (EBV-HLH) or Chronic Active EBV Infection (CAEBV)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The First Affiliated Hospital of Soochow University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The First Affiliated Hospital of Soochow University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      EBV-HLH and CAEBV are both caused by EBV infection, part of them can rapidly lead to a&#xD;
      syndrome of severe, life-threatening hyper-inflammation, with poor prognosis. Currently, the&#xD;
      most effective treatment remains unknown. This study is trying to evaluate the efficacy and&#xD;
      safety of PD-1 monoclonal antibody as a first-line therapy for EBV-HLH and CAEBV.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Eligible patients who were diagnosed with EBV-HLH or CAEBV, age between 12 and 70 years, were&#xD;
      enrolled in this study. All of them need to sign the informed consent first.&#xD;
&#xD;
      PD-1 monoclonal antibody 200mg is infused intravenously once for patients whose age &gt;=18&#xD;
      years, or age &lt;18 years but weight &gt;=40kg. While for patients age &lt;18 years, the dose of PD-1&#xD;
      monoclonal antibody is 3mg/kg. Besides, optimal supportive care is necessary.&#xD;
&#xD;
      Ruxolitinib and/or low-dose glucocorticoid can be used to reduce inflammation.&#xD;
&#xD;
      Cerebrospinal fluid parameters are examined, and methotrexate 15mg combined with&#xD;
      dexamethasone will be intrathecal injected without contraindications.&#xD;
&#xD;
      Clinical and laboratory indicators are investigated weekly to evaluate the efficacy and&#xD;
      toxicity.&#xD;
&#xD;
      If patients achieve partial response/complete response within 14 days after PD-1 monoclonal&#xD;
      antibody, the clinical observations are stopped. If not, the observation period is prolonged&#xD;
      to 21 days.&#xD;
&#xD;
      If disease progress at day 21, this study is terminated, and the patient should be transfer&#xD;
      to other treatments as soon as quickly.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 15, 2021</start_date>
  <completion_date type="Anticipated">April 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate</measure>
    <time_frame>3 weeks</time_frame>
    <description>complete response and/or partial response rate</description>
  </primary_outcome>
  <primary_outcome>
    <measure>EBV-DNA viral load</measure>
    <time_frame>3 weeks</time_frame>
    <description>EBV-DNA copy by polymerase chain reaction</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time for treatment works</measure>
    <time_frame>3 weeks</time_frame>
    <description>Time to achieve partial response or complete response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity of PD-1 monoclonal antibody</measure>
    <time_frame>3 weeks</time_frame>
    <description>Side effects related to immunotherapy</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>EBV Infection</condition>
  <arm_group>
    <arm_group_label>PD-1 monoclonal antibody group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PD-1 monoclonal antibody 200mg is infused intravenously once for patients whose age &gt;=18 years, or age &lt;18 years but weight &gt;=40kg. While for patients age &lt;18 years, the dose of PD-1 monoclonal antibody is 3mg/kg.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PD-1 monoclonal antibody</intervention_name>
    <description>PD-1 monoclonal antibody is a new attempt treatment, and ruxolitinib and/or low-dose dexamethasone can reduce the inflammation that occur in EBV-HLH or CAEBV.</description>
    <arm_group_label>PD-1 monoclonal antibody group</arm_group_label>
    <other_name>ruxolitinib</other_name>
    <other_name>dexamethasone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Meet the diagnostic criteria of EBV-HLH or CAEBV.&#xD;
&#xD;
          2. Newly diagnosed patients.&#xD;
&#xD;
          3. Eastern Cooperative Oncology Group score 0-3.&#xD;
&#xD;
          4. Total bilirubin &lt;= 10 times of upper limit of normal (except for those caused by&#xD;
             EBV-HLH or CAEBV), and serum creatinine &lt;= 1.5 times of upper limit of normal.&#xD;
&#xD;
          5. Serum HIV antigen or antibody is negative.&#xD;
&#xD;
          6. Hepatitis C virus (HCV) antibody is negative, or HCV antibody is positive, but HCV-RNA&#xD;
             is negative.&#xD;
&#xD;
          7. Both HbsAg and HbcAb for Hepatitis B virus (HBV) are negative. If not, the&#xD;
             quantification of HBV-DNA needs to be &lt;1*10e3 IU/ml.&#xD;
&#xD;
          8. The patient or his/her guardian must be able to understand and be willing to&#xD;
             participate in this study, and sign the informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Non EBV-HLH or CAEBV patients.&#xD;
&#xD;
          2. Refractory or relapsed EBV-HLH or CAEBV.&#xD;
&#xD;
          3. Heart function above grade II (NYHA).&#xD;
&#xD;
          4. Patients suffered from other uncontrollable active infections.&#xD;
&#xD;
          5. Pregnant or lactating women.&#xD;
&#xD;
          6. Patients with mental disorders and cannot cooperate with the requirements of research,&#xD;
             treatment and monitoring.&#xD;
&#xD;
          7. Active visceral bleeding.&#xD;
&#xD;
          8. Allergic to PD-1 monoclonal antibody.&#xD;
&#xD;
          9. Patients with known autoimmune diseases.&#xD;
&#xD;
         10. Participate in other clinical research at the same time.&#xD;
&#xD;
         11. The investigator judges that the patient has other reasons not suitable for this&#xD;
             study, or participating in the study will bring great risks to the patient.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xuefeng He, doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Affiliated Hospital of Soochow University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xuefeng He, doctor</last_name>
    <phone>86-18914031640</phone>
    <email>hexuefeng@suda.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Xiaoli Li, doctor</last_name>
    <phone>86-13625270981</phone>
    <email>397640784@qq.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Soochow University</name>
      <address>
        <city>Suzhou</city>
        <state>Jiangsu</state>
        <zip>215006</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xuefeng He, doctor</last_name>
      <phone>86-18914031640</phone>
      <email>hexuefeng@suda.edu.cn</email>
    </contact>
    <contact_backup>
      <last_name>Xiaoli Li, doctor</last_name>
      <phone>86-13625270981</phone>
      <email>397640784@qq.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>September 1, 2021</study_first_submitted>
  <study_first_submitted_qc>September 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 9, 2021</study_first_posted>
  <last_update_submitted>September 1, 2021</last_update_submitted>
  <last_update_submitted_qc>September 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Epstein-Barr Virus Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

